Ovarian Cancer Drugs Market 2028 By Drug Class, Distribution Channel and Geography | The Insight Partners

    Ovarian Cancer Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class (Alkylating Agents, Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR Inhibitors, PARP Inhibitors, Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

    Report Code: TIPRE00003750 | No. of Pages: 159 | Category: Pharmaceuticals | Status: Upcoming

    MARKET OVERVIEW



  • varian cancer is one of the most frequent cancers in women, affecting mostly women who have been through menopause. Bloating, pelvic or abdominal pain, tiredness, upset stomach, back pain, and other symptoms of ovarian cancer are common. Although the exact cause of ovarian cancer is unknown, women over the age of 50 who have a family history of the disease are at a higher risk of developing it. The key driving factors for the ovarian cancer drugs market are, growing prevalence of ovarian cancers along with rising product approvals to manage ovarian cancer.

    MARKET SCOPE



    The "Global Ovarian Cancer Drugs Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the ovarian cancer drugs market with detailed market segmentation by drug class and distribution channel. The report provides key statistics on the market status of the leading ovarian cancer drugs market players and offers key trends and opportunities in the market.

    MARKET SEGMENTATION



    • Based on drug class the market is segmented as, alkylating agents, mitotic inhibitors, antirheumatics, antipsoriatics, VEGF/VEGFR inhibitors, PARP inhibitors and others.
    • Based on distribution channel the market is segmented as, hospital pharmacies, retail pharmacies and online pharmacies.

    MARKET DYNAMICS


    Drivers:



    • Increasing prevalence of ovarian cancers is the key driver for the market growth.
    • Advancements in cancer treatments and presence of strong pipeline of drugs for management of ovarian cancers.
    • Extensive R&D efforts to develop novel drug therapies for treatment of ovarian cancer.
    • Early screening of cancers, icreasing awareness regarding cancer treatments are expected to fuel market growth during the forecast period.

    Restraints:



    • However, high cost of the drugs and possibility of side effects from the treatments are likley to restrain market growth during the forecast period.

    REGIONAL FRAMEWORK



    The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The ovarian cancer drugs market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

    The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the ovarian cancer drugs market in these regions.

    IMPACT OF COVID-19 ON OVARIAN CANCER DRUGS MARKET
    COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. There is big shift in demand for ovarian cancer drugs and therapeutics because of pandemic situation and lockdown scenes so that people cannot come out from their homes and can't take their cancer treatments which ultimately affecting the demand for ovarian cancer therapeutics and drugs. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.

    MARKET PLAYERS



    The report covers key developments in the ovarian cancer drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from ovarian cancer drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for ovarian cancer drugs in the global market.

    The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the ovarian cancer drugs market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

    • AstraZeneca
    • AbbVie Inc
    • F. Hoffmann-La Roche Ltd
    • Pfizer, Inc.
    • Merck Sharp and Dohme Corp
    • ImmunoGen, Inc
    • CLOVIS ONCOLOGY
    • Boehringer Ingelheim International GmbH
    • GlaxoSmithKline, Plc
    • Amgen Inc
    The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
  • TABLE OF CONTENTS

    1. INTRODUCTION
    1.1. SCOPE OF THE STUDY
    1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
    1.3. MARKET SEGMENTATION
    1.3.1 Ovarian Cancer Drugs Market - By Drug Class
    1.3.2 Ovarian Cancer Drugs Market - By Distribution Channel
    1.3.3 Ovarian Cancer Drugs Market - By Region
    1.3.3.1 By Country

    2. KEY TAKEAWAYS

    3. RESEARCH METHODOLOGY

    4. OVARIAN CANCER DRUGS MARKET LANDSCAPE
    4.1. OVERVIEW
    4.2. PORTER'S FIVE FORCES ANALYSIS
    4.2.1 Bargaining Power of Buyers
    4.2.1 Bargaining Power of Suppliers
    4.2.1 Threat of Substitute
    4.2.1 Threat of New Entrants
    4.2.1 Competitive Rivalry
    4.3. EXPERT OPINIONS

    5. OVARIAN CANCER DRUGS MARKET - KEY MARKET DYNAMICS
    5.1. KEY MARKET DRIVERS
    5.2. KEY MARKET RESTRAINTS
    5.3. KEY MARKET OPPORTUNITIES
    5.4. FUTURE TRENDS
    5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

    6. OVARIAN CANCER DRUGS MARKET - GLOBAL MARKET ANALYSIS
    6.1. OVARIAN CANCER DRUGS - GLOBAL MARKET OVERVIEW
    6.2. OVARIAN CANCER DRUGS - GLOBAL MARKET AND FORECAST TO 2028
    6.3. MARKET POSITIONING/MARKET SHARE

    7. OVARIAN CANCER DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
    7.1. OVERVIEW
    7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
    7.3. ALKYLATING AGENTS
    7.3.1. Overview
    7.3.2. Alkylating Agents Market Forecast and Analysis
    7.4. MITOTIC INHIBITORS
    7.4.1. Overview
    7.4.2. Mitotic Inhibitors Market Forecast and Analysis
    7.5. ANTIRHEUMATICS
    7.5.1. Overview
    7.5.2. Antirheumatics Market Forecast and Analysis
    7.6. ANTIPSORIATICS
    7.6.1. Overview
    7.6.2. Antipsoriatics Market Forecast and Analysis
    7.7. VEGF/VEGFR INHIBITORS
    7.7.1. Overview
    7.7.2. VEGF/VEGFR Inhibitors Market Forecast and Analysis
    7.8. PARP INHIBITORS
    7.8.1. Overview
    7.8.2. PARP Inhibitors Market Forecast and Analysis
    7.9. OTHERS
    7.9.1. Overview
    7.9.2. Others Market Forecast and Analysis
    8. OVARIAN CANCER DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
    8.1. OVERVIEW
    8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
    8.3. HOSPITAL PHARMACIES
    8.3.1. Overview
    8.3.2. Hospital Pharmacies Market Forecast and Analysis
    8.4. RETAIL PHARMACIES
    8.4.1. Overview
    8.4.2. Retail Pharmacies Market Forecast and Analysis
    8.5. ONLINE PHARMACIES
    8.5.1. Overview
    8.5.2. Online Pharmacies Market Forecast and Analysis

    9. OVARIAN CANCER DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
    9.1. NORTH AMERICA
    9.1.1 North America Ovarian Cancer Drugs Market Overview
    9.1.2 North America Ovarian Cancer Drugs Market Forecasts and Analysis
    9.1.3 North America Ovarian Cancer Drugs Market Forecasts and Analysis - By Drug Class
    9.1.4 North America Ovarian Cancer Drugs Market Forecasts and Analysis - By Distribution Channel
    9.1.5 North America Ovarian Cancer Drugs Market Forecasts and Analysis - By Countries
    9.1.5.1 Canada Ovarian Cancer Drugs Market
    9.1.5.1.1 Canada Ovarian Cancer Drugs Market by Drug Class
    9.1.5.1.2 Canada Ovarian Cancer Drugs Market by Distribution Channel
    9.1.5.2 Mexico Ovarian Cancer Drugs Market
    9.1.5.2.1 Mexico Ovarian Cancer Drugs Market by Drug Class
    9.1.5.2.2 Mexico Ovarian Cancer Drugs Market by Distribution Channel
    9.1.5.3 US Ovarian Cancer Drugs Market
    9.1.5.3.1 US Ovarian Cancer Drugs Market by Drug Class
    9.1.5.3.2 US Ovarian Cancer Drugs Market by Distribution Channel
    9.2. EUROPE
    9.2.1 Europe Ovarian Cancer Drugs Market Overview
    9.2.2 Europe Ovarian Cancer Drugs Market Forecasts and Analysis
    9.2.3 Europe Ovarian Cancer Drugs Market Forecasts and Analysis - By Drug Class
    9.2.4 Europe Ovarian Cancer Drugs Market Forecasts and Analysis - By Distribution Channel
    9.2.5 Europe Ovarian Cancer Drugs Market Forecasts and Analysis - By Countries
    9.2.5.1 Germany Ovarian Cancer Drugs Market
    9.2.5.1.1 Germany Ovarian Cancer Drugs Market by Drug Class
    9.2.5.1.2 Germany Ovarian Cancer Drugs Market by Distribution Channel
    9.2.5.2 France Ovarian Cancer Drugs Market
    9.2.5.2.1 France Ovarian Cancer Drugs Market by Drug Class
    9.2.5.2.2 France Ovarian Cancer Drugs Market by Distribution Channel
    9.2.5.3 Italy Ovarian Cancer Drugs Market
    9.2.5.3.1 Italy Ovarian Cancer Drugs Market by Drug Class
    9.2.5.3.2 Italy Ovarian Cancer Drugs Market by Distribution Channel
    9.2.5.4 Spain Ovarian Cancer Drugs Market
    9.2.5.4.1 Spain Ovarian Cancer Drugs Market by Drug Class
    9.2.5.4.2 Spain Ovarian Cancer Drugs Market by Distribution Channel
    9.2.5.5 United Kingdom Ovarian Cancer Drugs Market
    9.2.5.5.1 United Kingdom Ovarian Cancer Drugs Market by Drug Class
    9.2.5.5.2 United Kingdom Ovarian Cancer Drugs Market by Distribution Channel
    9.2.5.6 Rest of Europe Ovarian Cancer Drugs Market
    9.2.5.6.1 Rest of Europe Ovarian Cancer Drugs Market by Drug Class
    9.2.5.6.2 Rest of Europe Ovarian Cancer Drugs Market by Distribution Channel
    9.3. ASIA-PACIFIC
    9.3.1 Asia-Pacific Ovarian Cancer Drugs Market Overview
    9.3.2 Asia-Pacific Ovarian Cancer Drugs Market Forecasts and Analysis
    9.3.3 Asia-Pacific Ovarian Cancer Drugs Market Forecasts and Analysis - By Drug Class
    9.3.4 Asia-Pacific Ovarian Cancer Drugs Market Forecasts and Analysis - By Distribution Channel
    9.3.5 Asia-Pacific Ovarian Cancer Drugs Market Forecasts and Analysis - By Countries
    9.3.5.1 Australia Ovarian Cancer Drugs Market
    9.3.5.1.1 Australia Ovarian Cancer Drugs Market by Drug Class
    9.3.5.1.2 Australia Ovarian Cancer Drugs Market by Distribution Channel
    9.3.5.2 China Ovarian Cancer Drugs Market
    9.3.5.2.1 China Ovarian Cancer Drugs Market by Drug Class
    9.3.5.2.2 China Ovarian Cancer Drugs Market by Distribution Channel
    9.3.5.3 India Ovarian Cancer Drugs Market
    9.3.5.3.1 India Ovarian Cancer Drugs Market by Drug Class
    9.3.5.3.2 India Ovarian Cancer Drugs Market by Distribution Channel
    9.3.5.4 Japan Ovarian Cancer Drugs Market
    9.3.5.4.1 Japan Ovarian Cancer Drugs Market by Drug Class
    9.3.5.4.2 Japan Ovarian Cancer Drugs Market by Distribution Channel
    9.3.5.5 South Korea Ovarian Cancer Drugs Market
    9.3.5.5.1 South Korea Ovarian Cancer Drugs Market by Drug Class
    9.3.5.5.2 South Korea Ovarian Cancer Drugs Market by Distribution Channel
    9.3.5.6 Rest of Asia-Pacific Ovarian Cancer Drugs Market
    9.3.5.6.1 Rest of Asia-Pacific Ovarian Cancer Drugs Market by Drug Class
    9.3.5.6.2 Rest of Asia-Pacific Ovarian Cancer Drugs Market by Distribution Channel
    9.4. MIDDLE EAST AND AFRICA
    9.4.1 Middle East and Africa Ovarian Cancer Drugs Market Overview
    9.4.2 Middle East and Africa Ovarian Cancer Drugs Market Forecasts and Analysis
    9.4.3 Middle East and Africa Ovarian Cancer Drugs Market Forecasts and Analysis - By Drug Class
    9.4.4 Middle East and Africa Ovarian Cancer Drugs Market Forecasts and Analysis - By Distribution Channel
    9.4.5 Middle East and Africa Ovarian Cancer Drugs Market Forecasts and Analysis - By Countries
    9.4.5.1 South Africa Ovarian Cancer Drugs Market
    9.4.5.1.1 South Africa Ovarian Cancer Drugs Market by Drug Class
    9.4.5.1.2 South Africa Ovarian Cancer Drugs Market by Distribution Channel
    9.4.5.2 Saudi Arabia Ovarian Cancer Drugs Market
    9.4.5.2.1 Saudi Arabia Ovarian Cancer Drugs Market by Drug Class
    9.4.5.2.2 Saudi Arabia Ovarian Cancer Drugs Market by Distribution Channel
    9.4.5.3 U.A.E Ovarian Cancer Drugs Market
    9.4.5.3.1 U.A.E Ovarian Cancer Drugs Market by Drug Class
    9.4.5.3.2 U.A.E Ovarian Cancer Drugs Market by Distribution Channel
    9.4.5.4 Rest of Middle East and Africa Ovarian Cancer Drugs Market
    9.4.5.4.1 Rest of Middle East and Africa Ovarian Cancer Drugs Market by Drug Class
    9.4.5.4.2 Rest of Middle East and Africa Ovarian Cancer Drugs Market by Distribution Channel
    9.5. SOUTH AND CENTRAL AMERICA
    9.5.1 South and Central America Ovarian Cancer Drugs Market Overview
    9.5.2 South and Central America Ovarian Cancer Drugs Market Forecasts and Analysis
    9.5.3 South and Central America Ovarian Cancer Drugs Market Forecasts and Analysis - By Drug Class
    9.5.4 South and Central America Ovarian Cancer Drugs Market Forecasts and Analysis - By Distribution Channel
    9.5.5 South and Central America Ovarian Cancer Drugs Market Forecasts and Analysis - By Countries
    9.5.5.1 Brazil Ovarian Cancer Drugs Market
    9.5.5.1.1 Brazil Ovarian Cancer Drugs Market by Drug Class
    9.5.5.1.2 Brazil Ovarian Cancer Drugs Market by Distribution Channel
    9.5.5.2 Argentina Ovarian Cancer Drugs Market
    9.5.5.2.1 Argentina Ovarian Cancer Drugs Market by Drug Class
    9.5.5.2.2 Argentina Ovarian Cancer Drugs Market by Distribution Channel
    9.5.5.3 Rest of South and Central America Ovarian Cancer Drugs Market
    9.5.5.3.1 Rest of South and Central America Ovarian Cancer Drugs Market by Drug Class
    9.5.5.3.2 Rest of South and Central America Ovarian Cancer Drugs Market by Distribution Channel

    10. INDUSTRY LANDSCAPE
    10.1. MERGERS AND ACQUISITIONS
    10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
    10.3. NEW PRODUCT LAUNCHES
    10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

    11. OVARIAN CANCER DRUGS MARKET, KEY COMPANY PROFILES
    11.1. ABBVIE INC
    11.1.1. Key Facts
    11.1.2. Business Description
    11.1.3. Products and Services
    11.1.4. Financial Overview
    11.1.5. SWOT Analysis
    11.1.6. Key Developments
    11.2. ASTRAZENECA
    11.2.1. Key Facts
    11.2.2. Business Description
    11.2.3. Products and Services
    11.2.4. Financial Overview
    11.2.5. SWOT Analysis
    11.2.6. Key Developments
    11.3. F. HOFFMANN-LA ROCHE LTD
    11.3.1. Key Facts
    11.3.2. Business Description
    11.3.3. Products and Services
    11.3.4. Financial Overview
    11.3.5. SWOT Analysis
    11.3.6. Key Developments
    11.4. PFIZER, INC.
    11.4.1. Key Facts
    11.4.2. Business Description
    11.4.3. Products and Services
    11.4.4. Financial Overview
    11.4.5. SWOT Analysis
    11.4.6. Key Developments
    11.5. MERCK SHARP AND DOHME CORP
    11.5.1. Key Facts
    11.5.2. Business Description
    11.5.3. Products and Services
    11.5.4. Financial Overview
    11.5.5. SWOT Analysis
    11.5.6. Key Developments
    11.6. IMMUNOGEN, INC
    11.6.1. Key Facts
    11.6.2. Business Description
    11.6.3. Products and Services
    11.6.4. Financial Overview
    11.6.5. SWOT Analysis
    11.6.6. Key Developments
    11.7. CLOVIS ONCOLOGY
    11.7.1. Key Facts
    11.7.2. Business Description
    11.7.3. Products and Services
    11.7.4. Financial Overview
    11.7.5. SWOT Analysis
    11.7.6. Key Developments
    11.8. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    11.8.1. Key Facts
    11.8.2. Business Description
    11.8.3. Products and Services
    11.8.4. Financial Overview
    11.8.5. SWOT Analysis
    11.8.6. Key Developments
    11.9. GLAXOSMITHKLINE, PLC
    11.9.1. Key Facts
    11.9.2. Business Description
    11.9.3. Products and Services
    11.9.4. Financial Overview
    11.9.5. SWOT Analysis
    11.9.6. Key Developments
    11.10. AMGEN INC
    11.10.1. Key Facts
    11.10.2. Business Description
    11.10.3. Products and Services
    11.10.4. Financial Overview
    11.10.5. SWOT Analysis
    11.10.6. Key Developments

    12. APPENDIX
    12.1. ABOUT THE INSIGHT PARTNERS
    12.2. GLOSSARY OF TERMS
    "
    The List of Companies

    - AstraZeneca
    - AbbVie Inc
    - F. Hoffmann-La Roche Ltd
    - Pfizer, Inc.
    - Merck Sharp and Dohme Corp
    - ImmunoGen, Inc
    - CLOVIS ONCOLOGY
    - Boehringer Ingelheim International GmbH
    - GlaxoSmithKline, Plc
    - Amgen Inc
    - Oasmia Pharmaceuticals
    - Bayer
    - Lilly
    - Bristol-Myers Squibb
    TIPRE00003750
    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Get the Latest COVID-19 Analysis on this market




    Have a question?

    Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.


    Speak To Analyst
    Pricing
    • $3000
    • $4550
    • $6550
    • $8550
        GET FREE SAMPLE PDF

    Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

        Inquire for Discount